AMGN’s offer seems more like an act of desperation than a sign of confidence in the CVOT data. For payers, offering unfettered access to Repatha in return for the money-back option seems like a very bad tradeoff.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.